Pharmacyclics is committed to the development and commercialization of novel therapies intended to improve the quality and duration of life and to resolve serious unmet medical needs for cancer patients. Pharmacyclics is a wholly-owned subsidiary of AbbVie (NYSE:ABBV), a global, research-based biopharmaceutical company. Oncology is a key therapeutic area for AbbVie, with a portfolio consisting of three marketed products and a pipeline containing multiple promising new molecules that are being studied in more than 200 clinical trials for over 20 different types of cancer.

More than 1,200 Pharmacyclics and AbbVie research scientists, clinicians, marketing, operations and corporate professionals work in the San Francisco Bay Area. They combine their expertise in immuno-oncology, stem cells, and cell-signaling with their knowledge of bispecific antibodies, antibody-drug conjugates (ADCs), and covalent-inhibitor technologies to discover and develop novel cancer treatments. Together, we are striving to outsmart cancer.

Pharmaceutical

Pharmacyclics

The South San Francisco office focuses on strategic contracting, clinical research, and quality systems in the biopharmaceutical sector.

South San Francisco

Pharmacyclics' headquarters in Sunnyvale, CA, United States

The Schaffhausen office likely focuses on data analysis and clinical project management in the healthcare sector.

��

People (2)

Jobs (0)

Other offices

��������

People (2)

Jobs (0)

Other offices

��